SG166813A1 - 5-lipoxygenase-activating protein (flap) inhibitors - Google Patents

5-lipoxygenase-activating protein (flap) inhibitors

Info

Publication number
SG166813A1
SG166813A1 SG201008041-4A SG2010080414A SG166813A1 SG 166813 A1 SG166813 A1 SG 166813A1 SG 2010080414 A SG2010080414 A SG 2010080414A SG 166813 A1 SG166813 A1 SG 166813A1
Authority
SG
Singapore
Prior art keywords
flap
lipoxygenase
activating protein
inhibitors
compounds
Prior art date
Application number
SG201008041-4A
Other languages
English (en)
Inventor
John H Hutchinson
Petpiboon Peppi Prasit
Mark Moran
Jillian F Evans
Brian Andrew Stearns
Jeffrey Roger Roppe
Yiwei Li
Jasmine Eleanor Zunic
Jeannie M Arruda
Nicholas Simon Stock
Mustapha Haddach
Original Assignee
Amira Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amira Pharmaceuticals Inc filed Critical Amira Pharmaceuticals Inc
Publication of SG166813A1 publication Critical patent/SG166813A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
SG201008041-4A 2005-11-04 2006-10-30 5-lipoxygenase-activating protein (flap) inhibitors SG166813A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73403005P 2005-11-04 2005-11-04
US74717406P 2006-05-12 2006-05-12
US82334406P 2006-08-23 2006-08-23
US11/553,946 US7977359B2 (en) 2005-11-04 2006-10-27 5-lipdxygenase-activating protein (FLAP) inhibitors

Publications (1)

Publication Number Publication Date
SG166813A1 true SG166813A1 (en) 2010-12-29

Family

ID=38004604

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201008041-4A SG166813A1 (en) 2005-11-04 2006-10-30 5-lipoxygenase-activating protein (flap) inhibitors

Country Status (27)

Country Link
US (3) US7977359B2 (xx)
EP (2) EP2404904A1 (xx)
JP (3) JP4705986B2 (xx)
KR (1) KR101031766B1 (xx)
CN (1) CN102295637A (xx)
AT (1) ATE530521T1 (xx)
AU (2) AU2006311973B9 (xx)
BR (1) BRPI0618046A2 (xx)
CA (1) CA2628490C (xx)
CR (1) CR9942A (xx)
CY (1) CY1112383T1 (xx)
DK (1) DK1943219T3 (xx)
EA (2) EA015495B1 (xx)
ES (1) ES2373977T3 (xx)
HK (1) HK1114099A1 (xx)
HR (1) HRP20120033T1 (xx)
IL (2) IL190873A0 (xx)
MA (1) MA29931B1 (xx)
MY (1) MY151159A (xx)
NO (1) NO342361B1 (xx)
NZ (2) NZ592541A (xx)
PL (1) PL1943219T3 (xx)
PT (1) PT1943219E (xx)
RS (1) RS52189B (xx)
SG (1) SG166813A1 (xx)
SI (1) SI1943219T1 (xx)
WO (1) WO2007056021A2 (xx)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US20070225285A1 (en) * 2005-11-04 2007-09-27 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
GB2431927B (en) * 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) * 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US20070219206A1 (en) * 2005-11-04 2007-09-20 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US20070244128A1 (en) * 2005-11-04 2007-10-18 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
WO2008067566A1 (en) 2006-11-30 2008-06-05 Amira Pharmaceuticals, Inc. Compositions and treatments comprising 5-lipoxygenase-activating protein inhibitors and nitric oxide modulators
TW200920369A (en) * 2007-10-26 2009-05-16 Amira Pharmaceuticals Inc 5-lipoxygenase activating protein (flap) inhibitor
US20110160249A1 (en) * 2008-05-23 2011-06-30 Schaab Kevin Murray 5-lipoxygenase-activating protein inhibitor
WO2010027762A1 (en) * 2008-09-04 2010-03-11 Boehringer Ingelheim International Gmbh Indolizine inhibitors of leukotriene production
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
CN102264370A (zh) * 2008-12-23 2011-11-30 艾米拉制药公司 投与眼的flap抑制剂的局部调配物
JP2012513406A (ja) * 2008-12-23 2012-06-14 パンミラ ファーマシューティカルズ，エルエルシー． 皮膚科学の疾病の処置のためのｆｌａｐ阻害剤の局所製剤
EP3563842A1 (en) 2009-04-29 2019-11-06 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
EP2462128B1 (en) 2009-08-04 2016-09-21 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
WO2011038097A2 (en) * 2009-09-23 2011-03-31 Amira Pharmaceuticals, Inc. Indolizine inhibitors of 5-lipoxygenase
US20130005721A1 (en) * 2009-09-23 2013-01-03 Panmira Pharmaceuticals, Llc Indolizine inhibitors of 5-lipoxygenase
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
BR112012010525A2 (pt) 2009-11-03 2015-09-29 Glaxo Group Ltd novos processos
WO2012024150A1 (en) 2010-08-16 2012-02-23 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
US8580829B2 (en) 2010-08-26 2013-11-12 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
BR112013008638A2 (pt) * 2010-09-23 2016-06-21 Boehringer Ingelheim Int inibidores de oxadiazol de produção de leucotrieno
JP5828188B2 (ja) * 2010-09-23 2015-12-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン産生のオキサジアゾール阻害剤
LT2648726T (lt) 2010-12-07 2018-06-25 Amira Pharmaceuticals, Inc. Policiklinis lap1 antagonistas ir jo panaudojimai
JP2014508111A (ja) 2010-12-07 2014-04-03 アミラ ファーマシューティカルス，インコーポレーテッド リゾフォスファチジン酸受容体アンタゴニスト、その線維症の治療における使用
AU2012209696B2 (en) 2011-01-30 2015-09-03 Meiji Seika Pharma Co., Ltd. Topical antifungal agent
JP2014513077A (ja) 2011-04-05 2014-05-29 アミラ ファーマシューティカルス，インコーポレーテッド 線維症、疼痛、癌、ならびに呼吸器、アレルギー性、神経系または心血管疾患の治療に有用な３−または５−ビフェニル−４−イルイソキサゾールに基づく化合物
US9260416B2 (en) 2011-05-27 2016-02-16 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
AR089853A1 (es) 2012-02-01 2014-09-24 Boehringer Ingelheim Int Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso
AU2013297602A1 (en) 2012-07-30 2015-02-19 Meiji Seika Pharma Co., Ltd. Antitrichophytosis solution for external use
JP6124892B2 (ja) 2012-07-30 2017-05-10 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 抗白癬菌症貼付剤
WO2014031586A2 (en) * 2012-08-20 2014-02-27 Tallikut Pharmaceuticals, Inc. Methods for treating cardiovascular diseases
US10080748B2 (en) 2014-02-04 2018-09-25 Bioscience Pharma Partners, Llc Use of flap inhibitors to reduce neuroinflammation mediated injury in the central nervous system
US9533951B2 (en) * 2014-10-20 2017-01-03 Eastman Chemical Company Heterocyclic amphoteric compounds
CA2977947A1 (en) 2015-03-06 2016-09-15 Pharmakea, Inc. Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
CN105085401B (zh) * 2015-08-17 2018-02-13 北京大学 六氢吲唑类15‑脂氧合酶激活剂及应用
BR112019004517A2 (pt) 2016-09-07 2019-08-13 Pharmakea Inc formas cristalinas de um inibidor lisil-oxidase-semelhante 2 e métodos de preparação
EP4052707A1 (en) 2016-09-07 2022-09-07 Pharmakea, Inc. Uses of a lysyl oxidase-like 2 inhibitor
CN109890385B (zh) * 2016-10-28 2022-08-02 阿斯利康(瑞典)有限公司 (1r,2r)-2-[4-(3-甲基-1h-吡唑-5-基)苯甲酰基]-n-(4-氧代-4,5,6,7-四氢吡唑并[1,5-a]吡嗪-3-基)环己烷甲酰胺的结晶形式
CA3053918A1 (en) * 2017-02-16 2018-08-23 Autoimmune Pharma Llc Reduction of pro-inflammatory hdl using a leukotriene inhibitor
EP3628669A1 (en) * 2018-09-28 2020-04-01 GenKyoTex Suisse SA Novel compounds as nadph oxidase inhibitors
US20240317691A1 (en) * 2021-07-30 2024-09-26 The Regents Of The University Of California Compounds for Modulating Epithelial 15-(S)-Lipoxygenase-2 and Methods of Use for Same

Family Cites Families (207)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2431491A1 (fr) 1978-07-18 1980-02-15 Delalande Sa Nouveaux derives aminoalkoxy-5 benzofurannes et indoles, leur procede de preparation et leur application en therapeutique
DK151884C (da) * 1979-03-07 1988-06-13 Pfizer Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf
JPS60123485A (ja) * 1983-12-08 1985-07-02 Yoshitomi Pharmaceut Ind Ltd インド−ル−３−カルボキサミド誘導体
US5109009A (en) * 1985-03-08 1992-04-28 Leo Pharmaceutical Products Ltd. Quinoline and pyridine compounds and inhibition of 5-lipoxygenases therewith
IE58870B1 (en) * 1985-03-08 1993-11-17 Leo Pharm Prod Ltd Pyridine derivatives
DE3632411A1 (de) 1986-09-24 1988-04-07 Merck Patent Gmbh Verfahren zur herstellung von ethanderivaten
US5225421A (en) * 1986-12-17 1993-07-06 Merck Frosst Canada, Inc. 3-hetero-substituted-N-benzyl-indoles and medical methods of use therefor
NZ222878A (en) 1986-12-17 1991-02-26 Merck Frosst Canada Inc 3-hetero-substituted-n-benzyl-indole derivatives, and pharmaceutical compositions
US5081138A (en) * 1986-12-17 1992-01-14 Merck Frosst Canada, Inc. 3-hetero-substituted-n-benzyl-indoles and prevention of leucotriene synthesis therewith
MY103259A (en) 1987-04-15 1993-05-29 Ici America Inc Aliphatic carboxamides
NZ228721A (en) 1988-04-13 1992-02-25 Ici America Inc Substituted indoles and indazoles and pharmaceutical compositions
US5232916A (en) * 1988-06-27 1993-08-03 Merck Frosst Canada, Inc. Quinoline ether alkanoic acids
US5204344A (en) * 1989-08-22 1993-04-20 Merck Frosst Canada, Inc. (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes
NZ234883A (en) 1989-08-22 1995-01-27 Merck Frosst Canada Inc Quinolin-2-ylmethoxy indole derivatives, preparation and pharmaceutical compositions thereof
US5252585A (en) * 1992-02-03 1993-10-12 Merck Frosst Canada, Inc. Fluorinated quinoline indoles as inhibitors of the biosynthesis of leukotrienes
US5272145A (en) * 1989-08-22 1993-12-21 Merck Frosst Canada, Inc. (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes
NZ248177A (en) 1989-08-22 1995-01-27 Merck Frosst Canada Inc Benzyl phenyl hydrazine derivatives
CA1337427C (en) 1989-08-22 1995-10-24 Merck Frosst Canada Incorporated (quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
US5229516A (en) * 1989-10-27 1993-07-20 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
PT95692A (pt) 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
CA2032253C (en) 1989-12-15 2000-11-28 John W. Gillard 5-lipoxygenase activating protein
US5093356A (en) * 1990-01-16 1992-03-03 Merck Frosst Canada, Inc. Indenyl hydroxamic acids and hydroxy ureas as inhibitors of 5-lipoxygenase
US5081145A (en) * 1990-02-01 1992-01-14 Merck Frosst Canada, Inc. Indole-2-alkanoic acids compositions of and anti allergic use thereof
US5095031A (en) * 1990-08-20 1992-03-10 Abbott Laboratories Indole derivatives which inhibit leukotriene biosynthesis
JPH0764841B2 (ja) * 1990-10-03 1995-07-12 ファイザー製薬株式会社 インドール誘導体およびその用途
US5182367A (en) * 1990-11-30 1993-01-26 Merck & Co., Inc. 5-lipoxygenase activating protein
GB9108811D0 (en) 1991-04-24 1991-06-12 Erba Carlo Spa N-imidazolyl derivatives of substituted indole
US5202321A (en) * 1991-06-13 1993-04-13 Merck Frosst Canada, Inc. Thiopyrano[2,3,4-c,d]indoles as inhibitors of leukotriene biosynthesis
JPH06100551A (ja) 1991-09-06 1994-04-12 Dainippon Ink & Chem Inc 光学活性な２，５置換テトラヒドロフラン誘導体、その製造方法、その誘導体を含む液晶組成物及び液晶表示素子
US5308850A (en) * 1991-09-30 1994-05-03 Merck Frosst Canada, Inc. (Bicyclic-hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis
US5389650A (en) * 1991-09-30 1995-02-14 Merck Frosst Canada, Inc. (Azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis
US5190968A (en) * 1991-09-30 1993-03-02 Merck Frosst Canada, Inc. (Polycyclic-arylmethoxy) indoles as inhibitors of leukotriene biosynthesis
US5273980A (en) * 1991-09-30 1993-12-28 Merck Frosst Canada Inc. Bicyclic-azaarylmethoxy) indoles as inhibitors of leukotriene biosynthesis
US5290798A (en) * 1991-09-30 1994-03-01 Merck Frosst Canada, Inc. (hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis
CA2079374C (en) 1991-09-30 2003-08-05 Merck Frosst Canada Incorporated (bicyclic-azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis
ZA928276B (en) 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.
US5254567A (en) * 1991-11-15 1993-10-19 Merck Frosst Canada, Inc. Amorphous (quinolin-2-ylmethoxy)indole compounds which have useful pharmaceutical utility
CA2129429A1 (en) 1992-02-13 1993-08-14 Richard Frenette (azaaromaticalkoxy) indoles as inhibitors of leukotriene biosynthesis
CH683522A5 (de) 1992-03-13 1994-03-31 Hoffmann La Roche Verfahren zur Herstellung von Diarylen.
WO1993020065A1 (en) 1992-03-27 1993-10-14 Kyoto Pharmaceutical Industries, Ltd. Novel imidazole derivative, pharmaceutical use thereof, and intermediate therefor
MX9301088A (es) 1992-05-13 1993-11-01 Syntex Inc Derivados de indol, azaindol, y tetrahidro-1h-pirrol 2,3-c piridin-7-ona substituidos.
JPH0658881A (ja) 1992-06-12 1994-03-04 Mitsubishi Rayon Co Ltd 光学活性化合物の絶対配置判定法、絶対配置判定用試薬及び絶対配置判定装置
US5334719A (en) 1992-06-17 1994-08-02 Merck Frosst Canada, Inc. Bicyclic(azaaromatic)indoles as inhibitors of leukotriene bisynthesis
CA2136241C (en) 1992-06-22 2004-01-27 Richard Frenette Fluorinated quinoline indoles as inhibitors of the biosynthesis of leukotrienes
US5314898A (en) * 1992-06-29 1994-05-24 Merck & Co., Inc. Aryl thiopyrano[4,3,2-cd]indoles as inhibitors of leukotriene biosynthesis
US5314900A (en) 1992-11-19 1994-05-24 Merck Frosst Canada, Inc. Aryl thiopyrano[2,3,4-C,D]indoles as inhibitors of leukotriene biosynthesis
US5288743A (en) * 1992-11-20 1994-02-22 Abbott Laboratories Indole carboxylate derivatives which inhibit leukotriene biosynthesis
ZA939516B (en) 1992-12-22 1994-06-06 Smithkline Beecham Corp Endothelin receptor antagonists
JP3457694B2 (ja) 1993-02-04 2003-10-20 第一製薬株式会社 インフルエンザ感染予防・治療薬
US5374635A (en) * 1993-03-29 1994-12-20 Merck Frosst Canada, Inc. Furo[3,2-b]pyridines and thieno[3,2-b]pyridines as inhibitors of leukotriene biosynthesis
IL109309A (en) 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
BR9406823A (pt) 1993-06-14 1996-03-26 Pfizer Aminas secundárias e agentes anti-diabéticos e antiobesidade
JPH075651A (ja) 1993-06-14 1995-01-10 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料の処理方法
WO1995006637A1 (en) 1993-09-03 1995-03-09 Smithkline Beecham Plc Indole and indoline derivatives as 5ht1d receptor antagonists
DE4338770A1 (de) 1993-11-12 1995-05-18 Matthias Dr Lehr Indol-2-alkansäuren und ihre Derivate als Hemmstoffe der Phospholipase A¶2¶
US5399699A (en) * 1994-01-24 1995-03-21 Abbott Laboratories Indole iminooxy derivatives which inhibit leukotriene biosynthesis
US5420282A (en) * 1994-02-15 1995-05-30 Abbott Laboratories Thiopyrano(2,3,4-c,d) indolyloxime ether alkylcarboxylates
US5696076A (en) 1994-06-22 1997-12-09 Human Genome Sciences, Inc. 5-lipoxygenase-activating protein II
FR2721610B1 (fr) * 1994-06-28 1996-08-23 Adir Nouveaux dérivés (thia)cycloalkyl [b] indoles, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
JPH0820532A (ja) 1994-07-05 1996-01-23 Dai Ichi Seiyaku Co Ltd 抗膵炎剤
WO1996003377A1 (en) 1994-07-27 1996-02-08 Sankyo Company, Limited Heterocyclic compounds, useful as allosteric effectors at muscarinic receptors
TW396200B (en) * 1994-10-19 2000-07-01 Sumitomo Chemical Co Liquid crystal composition and liquid crystal element containing such composition
TW321649B (xx) 1994-11-12 1997-12-01 Zeneca Ltd
AU4514496A (en) 1994-12-13 1996-07-03 Smithkline Beecham Corporation Novel compounds
EP0820441B1 (en) 1995-04-10 2002-06-26 Fujisawa Pharmaceutical Co., Ltd. INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS
US5702637A (en) * 1995-04-19 1997-12-30 Minnesota Mining And Manufacturing Company Liquid crystal compounds having a chiral fluorinated terminal portion
EP0828712A1 (en) 1995-05-10 1998-03-18 Pfizer Inc. Beta-adrenergic agonists
JPH092977A (ja) 1995-06-21 1997-01-07 Dai Ichi Seiyaku Co Ltd 経口投与用医薬組成物
GB9523946D0 (en) 1995-11-23 1996-01-24 Bayer Ag Leukotriene antagonistic benzoic acid derivatives
ATE216384T1 (de) 1996-01-22 2002-05-15 Fujisawa Pharmaceutical Co Thiazolylbenzofuranderivate und pharmazeutische zusammensetzungen die sie enthalten
KR19980703369A (ko) 1996-01-29 1998-10-15 후루따 다께시 카르보닐 화합물의 환원 방법
US5756531A (en) 1996-04-30 1998-05-26 Abbott Laboratories Iminoxy derivatives of indole and indene compounds as inhibitors of prostaglandin biosynthesis
US5750558A (en) * 1996-06-06 1998-05-12 Abbott Laboratories Oxime derivatives of indole and indene compounds as inhibitors of prostaglandin biosynthesis
AU725735B2 (en) 1996-07-23 2000-10-19 Daiichi Pharmaceutical Co., Ltd. Absorption enhancer
US5877329A (en) * 1996-08-13 1999-03-02 Merck & Co., Inc. Palladium catalyzed indolization
WO1998021184A1 (en) 1996-11-14 1998-05-22 Pfizer Inc. Process for substituted pyridines
GB9710523D0 (en) 1997-05-23 1997-07-16 Smithkline Beecham Plc Novel compounds
AU7552198A (en) 1997-06-11 1998-12-30 Sankyo Company Limited Benzylamine derivatives
JPH1180032A (ja) 1997-09-12 1999-03-23 Dai Ichi Seiyaku Co Ltd 複合体
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
ATE293599T1 (de) 1997-12-24 2005-05-15 Aventis Pharma Gmbh Indolderivate als faktor xa inhibitoren
WO1999033458A1 (fr) 1997-12-25 1999-07-08 Daiichi Pharmaceutical Co., Ltd. Composition medicinale pour administration percutanee
JPH11189531A (ja) 1997-12-26 1999-07-13 Dai Ichi Seiyaku Co Ltd 経粘膜投与用医薬組成物
JPH11193265A (ja) 1997-12-26 1999-07-21 Dai Ichi Seiyaku Co Ltd ３−（７−アミジノ−２−ナフチル）−２−フェニルプロピオン酸誘導体の塩
CA2260499A1 (en) 1998-01-29 1999-07-29 Sumitomo Pharmaceuticals Company Limited Pharmaceutical compositions for the treatment of ischemic brain damage
EE200000522A (et) 1998-02-25 2002-02-15 Genetics Institute, Inc. Fosfolipaas A2 ensüümi inhibiitor, seda sisaldav farmatseutiline kompositsioon ning meetod fosfolipaasensüümi toime pärssimiseks
US6500853B1 (en) * 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
EP1071710B2 (en) * 1998-04-15 2011-11-02 Merck Serono Biodevelopment Genomic sequence of the 5-lipoxygenase-activating protein (flap), polymorphic markers thereof and methods for detection of asthma
NZ508790A (en) 1998-05-22 2003-10-31 Scios Inc Heterocyclic compounds and methods to treat cardiac failure and other disorders
US6867209B1 (en) * 1998-05-22 2005-03-15 Scios, Inc. Indole-type derivatives as inhibitors of p38 kinase
JP2000007590A (ja) 1998-06-23 2000-01-11 Daicel Chem Ind Ltd 置換芳香族化合物の製造方法
CA2350415A1 (en) 1998-11-18 2000-05-25 Incyte Pharmaceuticals, Inc. Inflammation-associated genes
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
JP2000302671A (ja) 1999-04-27 2000-10-31 Hitoshi Sezaki 経口投与用医薬組成物
ATE376547T1 (de) 1999-05-21 2007-11-15 Scios Inc Derivate des indol-typs als p38 kinase inhibitoren
SK3832002A3 (en) 1999-09-21 2002-11-06 Astrazeneca Ab Quinazoline compounds and pharmaceutical compositions containing them
DE19948417A1 (de) * 1999-10-07 2001-04-19 Morphochem Ag Imidazol-Derivate und ihre Verwendung als Arzneimittel
AU7962200A (en) 1999-10-29 2001-05-14 Wakunaga Pharmaceutical Co., Ltd Novel indole derivatives and drugs containing the same as the active ingredient
JP2001139462A (ja) 1999-11-10 2001-05-22 Dai Ichi Seiyaku Co Ltd 新規製剤
US6492393B1 (en) 1999-11-16 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
AU2050001A (en) 1999-12-16 2001-06-25 Eli Lilly And Company Synthesis of indole-containing spla2 inhibitors
US7345051B2 (en) 2000-01-31 2008-03-18 Genaera Corporation Mucin synthesis inhibitors
GB0003079D0 (en) 2000-02-10 2000-03-29 Glaxo Group Ltd Novel protein
AU2001234958A1 (en) 2000-02-11 2001-08-20 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
US6436965B1 (en) 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
NZ521192A (en) 2000-03-09 2005-01-28 Ono Pharmaceutical Co Indole derivatives, process for preparation of the same and use thereof
US6476037B1 (en) 2000-03-23 2002-11-05 The Regents Of The University Of California L-arginine and phosphodiesterase (PDE) inhibitor synergism
US20010039037A1 (en) * 2000-04-05 2001-11-08 Lee Harland Novel polypeptide
JP2003530121A (ja) 2000-04-07 2003-10-14 バイエル アクチェンゲゼルシャフト ヒトｃｙｓｌｔ２様ｇｐｃｒ蛋白の調節
MXPA02010763A (es) * 2000-06-14 2003-03-10 Warner Lambert Co Heterociclicos biciclos-6,5 fusionados.
AU2001267823A1 (en) 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Compounds exhibiting x-type spla2 inhibiting effect
DE10037310A1 (de) 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
EP1326835A1 (en) 2000-10-05 2003-07-16 Fujisawa Pharmaceutical Co., Ltd. Benzamide compounds as apo b secretion inhibitors
CN1289072C (zh) 2000-12-22 2006-12-13 石原产业株式会社 苯胺衍生物或其盐以及含有它们的细胞因子产生抑制剂
CA2432654A1 (en) 2000-12-22 2002-07-04 Wyeth Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands
CA2436130A1 (en) * 2001-01-29 2002-08-08 3-Dimensional Pharmaceuticals, Inc. Substituted indoles and their use as integrin antagonists
JP2002226429A (ja) 2001-02-06 2002-08-14 Fuji Photo Film Co Ltd アクリル酸エステル化合物の製造方法
US6627646B2 (en) 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
WO2003022813A1 (fr) 2001-09-07 2003-03-20 Ono Pharmaceutical Co., Ltd. Derives indole, methode de fabrication et medicaments renfermant lesdits derives en tant que principe actif
CA2459515A1 (en) 2001-09-07 2003-03-20 Kazuhiko Torisu Indole derivatives
WO2003035625A1 (en) 2001-09-19 2003-05-01 Pharmacia Corporation Substituted indazole compounds for the treatment of inflammation
DE10147672A1 (de) 2001-09-27 2003-04-10 Bayer Ag Substituierte 2,5-Diamidoindole und ihre Verwendung
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
WO2003050174A1 (en) 2001-12-11 2003-06-19 Rhodia Chimie Catalytic pgm mixture for hydrosilylation
USH2153H1 (en) * 2002-04-24 2006-04-04 Smithkline Beecham Corp. Association of asthma with polymorphisms in the cysteinyl leukotriene 2 receptor
US20050187249A1 (en) 2002-05-13 2005-08-25 Daiichi Pharmaceutical Co., Ltd. Lypohilization product
AR037647A1 (es) 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
JPWO2004000795A1 (ja) 2002-06-20 2005-10-20 協和醗酵工業株式会社 ビニルパーフルオロアルカンスルホン酸エステル誘導体の製造法
AU2003243709B2 (en) 2002-06-24 2007-01-18 Schering Corporation Indole derivatives useful as histamine H3 antagonists
US20040087590A1 (en) 2002-08-23 2004-05-06 University Of Connecticut Novel biphenyl and biphenyl-like cannabinoids
WO2004017917A2 (en) 2002-08-26 2004-03-04 Merck & Co., Inc. Method for the prevention and/or treatment of atherosclerosis
PT1537078E (pt) 2002-08-29 2010-06-18 Merck Sharp & Dohme Indoles que possuem actividade antidiabética
US7851486B2 (en) 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
WO2004048331A1 (en) 2002-11-28 2004-06-10 Suven Life Sciences Limited N-arylalkyl-3-aminoalkoxyindoles and their use as 5-ht ligands
US7642277B2 (en) 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
US20040198800A1 (en) * 2002-12-19 2004-10-07 Geoffrey Allan Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents
GB0301350D0 (en) 2003-01-21 2003-02-19 Merck Sharp & Dohme Therapeutic agents
JP4513351B2 (ja) 2003-02-12 2010-07-28 チッソ株式会社 結合基にフッ素化されたアルキル基を有する液晶性化合物、液晶組成物および液晶表示素子
JPWO2004078719A1 (ja) 2003-03-06 2006-06-08 小野薬品工業株式会社 インドール誘導体化合物およびその化合物を有効成分とする薬剤
EP1479677A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH New indole derivatives as factor xa inhibitors
WO2004108671A1 (en) 2003-06-06 2004-12-16 Suven Life Sciences Limited Substituted indoles with serotonin receptor affinity, process for their preparation and pharmaceutical compositions containing them
CN1829519A (zh) 2003-07-24 2006-09-06 默克公司 二苯基取代的环烷烃类,含有它们的组合物和应用的方法
JP4949027B2 (ja) 2003-08-25 2012-06-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 液晶媒体
CA2537097A1 (en) 2003-09-04 2005-03-17 Aventis Pharmaceuticals Inc. Substituted indoles as inhibitors of poly (adp-ribose) polymerase (parp)
ZA200601978B (en) 2003-09-05 2007-05-30 Neurogen Corp Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands
JP4363133B2 (ja) 2003-09-09 2009-11-11 東洋インキ製造株式会社 有機エレクトロルミネッセンス用素子材料およびそれを用いた有機エレクトロルミネッセンス素子
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
ES2314460T3 (es) 2003-10-31 2009-03-16 Otsuka Pharmaceutical Co., Ltd. Compuestos de 2,3-dihidro-6-nitroimidazo (2,1-b)oxazol para el tratamiento de la tuberculosis.
JP2005170939A (ja) 2003-11-20 2005-06-30 Takeda Chem Ind Ltd 糖尿病の予防・治療剤
ES2299906T3 (es) 2003-11-25 2008-06-01 Eli Lilly And Company Moduladores de receptores activados por proliferadores de peroxisomas.
WO2005054213A1 (ja) 2003-12-02 2005-06-16 Shionogi & Co., Ltd. ペルオキシソーム増殖活性化受容体アゴニスト活性を有するイソキサゾール誘導体
JP2007513128A (ja) 2003-12-03 2007-05-24 メルク　エンド　カムパニー　インコーポレーテッド アルツハイマー病および関連状態の治療に有用な１−アルキル−３−チオ置換インドール−２−アルキン酸
WO2005066151A2 (en) 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP5142450B2 (ja) 2003-12-25 2013-02-13 徹也 西尾 ジアミノ化合物、ビニル化合物、高分子化合物、配向膜、該配向膜を用いた有機半導体装置、導電性高分子、該導電性高分子を使用したエレクトロルミネッセンス素子、液晶配向膜、及び該液晶配向膜を用いた光学素子
US7064203B2 (en) 2003-12-29 2006-06-20 Bristol Myers Squibb Company Di-substituted pyrrolotriazine compounds
WO2005066157A1 (en) 2004-01-02 2005-07-21 Suven Life Sciences 3-(pyrolidin-3-l) indoles as 5-ht6 receptor modulators
JP2005194250A (ja) 2004-01-09 2005-07-21 Sumitomo Chemical Takeda Agro Co Ltd トリアゾール化合物、その製造法および用途
US8158362B2 (en) 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
EP1727533A1 (en) 2004-02-26 2006-12-06 Merck & Co., Inc. Use of cysteinyl leukotriene 2 receptor antagonists
WO2005097203A2 (en) 2004-04-01 2005-10-20 Cardiome Pharma Corp. Serum protein conjugates of ion channel modulating compounds and uses thereof
CN101031289A (zh) 2004-04-26 2007-09-05 范德比尔特大学 作为具有降低胃肠毒性的治疗剂的吲哚乙酸和茚乙酸衍生物
DK1756096T3 (da) * 2004-05-03 2009-10-26 Hoffmann La Roche Indolylderivater som lever-X-receptormodulatorer
ES2321422T3 (es) 2004-06-18 2009-06-05 Biolipox Ab Indoles utiles para el tratamiento de la inflamacion.
CN1980659A (zh) 2004-07-02 2007-06-13 默克公司 具有抗糖尿病活性的吲哚类
WO2006023843A2 (en) 2004-08-20 2006-03-02 Bayer Pharmaceuticals Corporation Novel heterocycles
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006041961A1 (en) 2004-10-05 2006-04-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTHAND HUMAN SERVICES Arylthioindole tubulin polymerization inhibitors and methods of treating or preventing cancer using same
EP1814877B1 (en) 2004-10-18 2009-03-11 Merck & Co., Inc. Diphenyl substituted alkanes as flap inhibitors
ATE469154T1 (de) 2005-01-14 2010-06-15 Janssen Pharmaceutica Nv Pyrazolopyrimidine als zellzyklus-kinasehemmer
EP1844013A1 (en) 2005-01-19 2007-10-17 Biolipox AB Indoles useful in the treatment of inflammation
JP2008527030A (ja) 2005-01-19 2008-07-24 バイオリポックス エービー 炎症の治療に有用なインドール類
EA200701504A1 (ru) 2005-01-19 2008-02-28 Биолипокс Аб Индолы, пригодные для лечения воспалений
EP1838669A1 (en) 2005-01-19 2007-10-03 Biolipox AB Indoles useful in the treatment of inflammation
AU2006223508A1 (en) 2005-03-09 2006-09-21 Merck Frosst Canada Ltd Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use
CA2601979C (en) 2005-04-21 2014-06-17 Laboratoires Serono S.A. 2,3 substituted pyrazine sulfonamides
JP5846711B2 (ja) 2005-06-09 2016-01-20 メダ アーベー 炎症性疾患の治療のための方法及び組成物
GB0516156D0 (en) 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors
US7829535B2 (en) 2005-08-18 2010-11-09 Accelalox, Inc. Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway
US7394658B2 (en) 2005-09-01 2008-07-01 Harman International Industries, Incorporated Heat sink with twist lock mounting mechanism
SI1945622T1 (sl) 2005-10-11 2012-05-31 Univ Pittsburgh Izotopično markirane spojine benzfurana kot označevalne snovi za amiloidogenske proteine
US7405302B2 (en) * 2005-10-11 2008-07-29 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
JP2009512716A (ja) 2005-10-21 2009-03-26 ユニバーシティ・オブ・アラバマ・アット・バーミンガム Ｈｉｖ−１キャプシド構築の低分子阻害剤
UY29896A1 (es) 2005-11-04 2007-06-29 Astrazeneca Ab Nuevos derivados de cromano, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
NL2000284C2 (nl) 2005-11-04 2007-09-28 Pfizer Ltd Pyrazine-derivaten.
UY29892A1 (es) 2005-11-04 2007-06-29 Astrazeneca Ab Nuevos derivados de cromano, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones
US20070244128A1 (en) * 2005-11-04 2007-10-18 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US20070219206A1 (en) 2005-11-04 2007-09-20 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US20070225285A1 (en) * 2005-11-04 2007-09-27 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
AR059901A1 (es) 2006-03-20 2008-05-07 Bayer Pharmaceuticals Corp Compuestos de tetrahidropiridotienopirimidina utiles para tratar o prevenir trastornos proliferativos celulares.
TW200815377A (en) 2006-04-24 2008-04-01 Astellas Pharma Inc Oxadiazolidinedione compound
CA2656564C (en) 2006-06-29 2015-06-16 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
JP2009023986A (ja) 2006-11-08 2009-02-05 Pharma Ip 抗癌剤としてのビアリール誘導体
WO2008058341A1 (en) 2006-11-15 2008-05-22 Cytopia Research Pty Ltd Inhibitors of kinase activity
WO2008067566A1 (en) 2006-11-30 2008-06-05 Amira Pharmaceuticals, Inc. Compositions and treatments comprising 5-lipoxygenase-activating protein inhibitors and nitric oxide modulators
WO2008097930A1 (en) 2007-02-05 2008-08-14 Amira Pharmaceuticals, Inc. Reverse indoles as 5-lipoxygenase-activating protein (flap) inhibitors
US8039505B2 (en) * 2007-04-11 2011-10-18 University Of Utah Research Foundation Compounds for modulating T-cells
WO2009002746A1 (en) 2007-06-22 2008-12-31 Decode Genetics Ehf. Dosing schedules of leukotriene synthesis inhibitors for human therapy
US8124605B2 (en) 2007-07-06 2012-02-28 Kinex Pharmaceuticals, Llc Compositions and methods for modulating a kinase cascade
US20100298343A1 (en) 2007-10-05 2010-11-25 John Howard Hutchinson 5-lipoxygenase-activating protein (flap) inhibitors
TW200920369A (en) 2007-10-26 2009-05-16 Amira Pharmaceuticals Inc 5-lipoxygenase activating protein (flap) inhibitor
EP2269076A4 (en) 2008-03-14 2011-04-06 Nat Jewish Health METHODS FOR DETERMINING SENSITIVITY TO TREATMENT WITH LEUCOTRIENE MODIFIERS
US20110160249A1 (en) 2008-05-23 2011-06-30 Schaab Kevin Murray 5-lipoxygenase-activating protein inhibitor
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors

Also Published As

Publication number Publication date
NZ592541A (en) 2012-11-30
EP2404904A1 (en) 2012-01-11
HK1114099A1 (xx) 2008-10-24
NO20081838L (no) 2008-07-29
IL213107A0 (en) 2011-07-31
US7977359B2 (en) 2011-07-12
EP1943219A2 (en) 2008-07-16
HRP20120033T1 (hr) 2012-02-29
JP4705986B2 (ja) 2011-06-22
PT1943219E (pt) 2011-12-19
EA200801163A1 (ru) 2008-10-30
MY151159A (en) 2014-04-30
EA015495B1 (ru) 2011-08-30
US20110118315A1 (en) 2011-05-19
IL190873A0 (en) 2008-11-03
ES2373977T3 (es) 2012-02-10
US20140018394A1 (en) 2014-01-16
JP2009528975A (ja) 2009-08-13
US20070105866A1 (en) 2007-05-10
JP5451347B2 (ja) 2014-03-26
JP2011105752A (ja) 2011-06-02
KR20080070055A (ko) 2008-07-29
AU2010241356B2 (en) 2011-07-28
AU2006311973B2 (en) 2010-12-02
CR9942A (es) 2008-10-29
PL1943219T3 (pl) 2012-05-31
WO2007056021A2 (en) 2007-05-18
NZ567718A (en) 2011-07-29
NO342361B1 (no) 2018-05-14
CN102295637A (zh) 2011-12-28
CY1112383T1 (el) 2015-12-09
EP1943219B8 (en) 2012-03-07
DK1943219T3 (da) 2012-01-30
BRPI0618046A2 (pt) 2013-01-08
WO2007056021A3 (en) 2007-07-12
CA2628490C (en) 2012-05-22
KR101031766B1 (ko) 2011-04-29
AU2006311973A1 (en) 2007-05-18
RS52189B (en) 2012-10-31
EP1943219A4 (en) 2010-06-02
MA29931B1 (fr) 2008-11-03
JP2010090144A (ja) 2010-04-22
US8710081B2 (en) 2014-04-29
JP5506707B2 (ja) 2014-05-28
EA018616B1 (ru) 2013-09-30
ATE530521T1 (de) 2011-11-15
SI1943219T1 (sl) 2012-02-29
EP1943219B1 (en) 2011-10-26
CA2628490A1 (en) 2007-05-18
AU2006311973B9 (en) 2010-12-16
AU2010241356A1 (en) 2010-12-02
EA201000584A1 (ru) 2010-10-29

Similar Documents

Publication Publication Date Title
SG166813A1 (en) 5-lipoxygenase-activating protein (flap) inhibitors
SG165387A1 (en) 5-lipoxygenase-activating protein (flap) inhibitors
EA017150B9 (ru) Ингибиторы белка, активирующего 5-липоксигеназу (flap)
WO2007047207A3 (en) 5-lipoxygenase-activating protein (flap) inhibitors
WO2009045700A3 (en) 5-lipoxygenase-activating protein (flap) inhibitors
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
UY31073A1 (es) Inhibidores de la proteína activadora de la 5-lipoxigenasa (flap)
WO2010021693A3 (en) Mif modulators
IL189178A0 (en) Thiazolyl derivatives and pharmaceutical compositions containing the same
WO2009035818A8 (en) Compounds that modulate intracellular calcium
WO2010025295A3 (en) Compounds that modulate intracellular calcium
WO2009076454A3 (en) Compounds that modulate intracellular calcium
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
WO2009044173A3 (en) Methods of treating cancer using notch pathway inhibitors
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
MY144970A (en) Heterocyclic compounds
WO2010034015A3 (en) Modulating the alternative complement pathway
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
HK1102626A1 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
TW200738244A (en) 20-Alkyl, gemini vitamin D3 compounds and methods of use thereof
DE602006018461D1 (de) Galk1s als modifikatoren des pten/akt-wegs
WO2006031930A3 (en) Modulation of xbp-1 activity for treatment of metabolic disorders
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors
WO2006072951A3 (en) Compositions and methods for regulating apoptosis
UA97289C2 (ru) Соединения и их композиция как модуляторы gpr119 активности